Saniona Appoints Chief Legal Officer and Chief Technical Operations Officer to Its Govt Group

“This has been a 12 months of transformation for Saniona, evolving from a firm focused on early-stage exploration to one particular capable of conducting its possess mid-phase scientific trials. As we near out 2020, the employing of Denelle and Kyle completes Saniona’s government workforce in guidance of our present enterprise,” stated Rami Levin, President and CEO of Saniona. “As we look to 2021, our entire organization is concentrated on initiating Period 2b medical trials of Tesomet in HO and PWS, as perfectly as advancing SAN711, the 1st drug applicant from our library of far more than 20,000 proprietary ion channel modulators, into the clinic.”

Denelle Waynick, Main Lawful Officer, has nearly 30 decades of encounter advising domestic and international organizations in the healthcare and existence sciences industries. Most lately, Waynick served as Main Authorized Officer and Corporate Secretary at MyoKardia, where by she delivered strategic and practical counsel to C-suite executives in authorized issues, as perfectly as issues impacted by the regulatory and coverage ecosystem. Waynick has also labored as in-property corporate counsel at UCB, Actavis and Schering-Plough, and in corporate law as an Affiliate and Associate at nationwide and regional legislation companies. In addition to abilities in corporate, policy, governance and litigation issues, she has served as counsel on a vary of international business enterprise transactions, together with mergers, acquisitions and divestments. Waynick holds a B.S. in Accounting from Rutgers, the Condition College of New Jersey-Newark, and a JD from Howard University Faculty of Regulation.

“Saniona is a organization uniquely positioned for lengthy-phrase good results — with both equally a mid-phase products in clinical advancement and a sturdy exploration motor to additional its pipeline. I am psyched about joining the group and contributing to Saniona’s strong progress,” stated Waynick.

Kyle Haraldsen, Chief Specialized Functions Officer, has virtually 20 years of complex functions and production expertise in the biopharmaceutical industry, like in assist of U.S. and E.U. product or service approvals. Most just lately, he served as the Vice President of Technological Functions and Job Management at AMAG Prescription drugs, wherever he led the system and analytical progress, producing, offer chain and venture administration features. Throughout his time at AMAG, Haraldsen oversaw numerous merchandise launches, line extensions and the integration of two growth stage belongings. Prior to his time at AMAG, he was the Senior Director of Manufacturing at Radius Health, exactly where he was dependable for the developmental, operational, and budgetary oversight of CMC packages and scientific demo product in guidance of world Period 3 and multinational Period 2 clinical trials. Haraldsen also labored for agreement companies Avecia Biotechnology and Johnson Matthey Pharma Products and services. He holds a B.S. in Chemical Engineering from Northeastern University.

“As Saniona prepares to execute sizeable scientific trial applications, it will be important that we have a sturdy technological operations functionality to oversee the production and supply of merchandise in line with scientific enhancement actions and timelines. I am keen to ensure we have the people and processes in area to aid prosperous execution of our scientific programs, and to get started arranging pre-industrial manufacturing and offer chain technique,” mentioned Haraldsen.

Waynick and Haraldsen will provide on Saniona’s government committee and will report to President and CEO Rami Levin. Both positions will be based in Saniona’s business office in the Boston, Massachusetts-spot, U.S. Waynick and Haraldsen will commence in January 2021.

For far more information and facts, make sure you call

Trista Morrison, Main Communications Officer, Saniona. Business office: + 1 (781) 810-9227. E-mail: [email protected]

The info was submitted for publication, through the company of the make contact with human being set out earlier mentioned, at 14:00 CET on December 21, 2020.

About Saniona
Saniona is a biopharmaceutical organization focused on finding, acquiring, and delivering modern treatment options for rare disease clients all-around the earth. The company’s lead products candidate, Tesomet, is in mid-phase scientific trials for the unusual health conditions Prader-Willi syndrome and hypothalamic weight problems. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead applicant SAN711 coming into Phase 1 research for exceptional neuropathic disorders. Saniona intends to establish and commercialize its rare disease products and solutions internally. The business has out-accredited other systems, which might deliver upcoming supplemental revenue. Saniona is centered in Copenhagen, Denmark and Boston, Mass., U.S. The firm’s shares are outlined on Nasdaq Stockholm Modest Cap (OMX: SANION). Study much more at www.saniona.com.

Attachment

• Dec New Hires Push Launch 12.21.20 (Uk)

COMTEX_376592149/2471/2020-12-21T08:00:53

Is there a problem with this push release? Get in touch with the supply supplier Comtex at [email protected]. You can also make contact with MarketWatch Purchaser Assistance by means of our Shopper Center.

(C) Copyright 2020 GlobeNewswire, Inc. All legal rights reserved.